Adaptive Biotechnologies Corporation · NASDAQ:ADPT

Adaptive Biotechnologies — Q1 2026 Earnings Presentation

11 slides from Adaptive Biotechnologies's earnings presentation, 2026

  1. Slide 1: First Quarter 2026 Earnings Conference Call

    First Quarter 2026 Earnings Conference Call

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation has been prepared by Adaptive Biotechnologies Corporation (“we,” “us,” “our,” “Adaptive” or the “Company”) and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements co

  3. Slide 3: Q1 highlights – off to a strong start across the board

    Q1 highlights – off to a strong start across the board +53% +41% 74% ~$222M MRD revenue clonoSEQ tests Total company Total cash2 position growth Y/Y delivered Y/Y gross margin $67.1M revenue 32,595 tests in Q1’26 70% sequencing GM1 $5.3M cash2 burn +48% ex-milestones +9% Q/Q growth +8 ppt seq. GM1 Y

  4. Slide 4: Clinical testing: Strong volume growth with key metrics strengthening

    Clinical testing: Strong volume growth with key metrics strengthening Clinical testing revenue increased 54% Y/Y 16% Q1’26 contribution from NHL (DLBCL +19% Q/Q) clonoSEQ test volumes 32,595 30,038 49% of MRD tests in blood in Q1’26 27,111 9% 25,321 11% 35% Q1’26 contribution from community setting

  5. Slide 5: MRD pharma: Strong performance creates halo effect in clinical testing

    MRD pharma: Strong performance creates halo effect in clinical testing Revenue growth of 53% Y/Y Highest ever quarter for new bookings Q1’ 2026 33% Y/Y growth excluding milestones ~$254M in backlog (24% increase Y/Y) MRD pharma   revenue  1st MRD U.S. primary endpoint milestone  Growth driven by

  6. Slide 6: 2026 MRD key goals progress

    2026 MRD key goals progress Goals set at beginning of 2026 Progress to annual goals clonoSEQ test volumes: >30% growth ‘26/’25 35% growth ‘26/’25  Increase testing in blood: >50%  On track (at 49% in Q1’26)  Community presence: >35%  On track (at 35% in Q1’26)  EMR integrations: integrate ~40 a

  7. Slide 7: IM 2026 key goals and progress

    IM 2026 key goals and progress GOALS PROGRESS TCR-antigen binding data & AI predictions  Scaling size, breadth and quality of TCR-antigen data  Scale data generation and AI/ML modeling  Established industry leading, high accuracy proprietary ‘digital’ modeling approach  Improve prediction perfor

  8. Slide 8: Q1 2026 financial highlights

    Q1 2026 financial highlights Q1 Revenue and Operating Expenses ($M) Total Revenue1 Total OPEX MRD $90.12 Immune Medicine $70.9 +45% $82.02 21.0 3.8 -26% 17.4 10% G&A $48.81 23.0 26.3 S&M 5.11 67.1 +53% 23.6 24.2 R&D 43.7 17.0 18.7 COR Q1 2025 Q1 2026 Q1 2025 Q1 2026 Segment Performance ($M) ($M) MRD

  9. Slide 9: FY 2026 updated guidance

    FY 2026 updated guidance  FY 2026 revenue guidance:  MRD revenue between $260M and $270M vs previous guidance between $255M and $265M  MRD milestones of $9M (all recognized in Q1’26)  FY 2026 operating expenses guidance:  OPEX between $350M and $360M (unchanged) On track to achieve positive adj

  10. Slide 10: Appendix: Reconciliations between Adjusted EBITDA and net loss

    Appendix: Reconciliations between Adjusted EBITDA and net loss attributable to Adaptive Biotechnologies Corporation & Segment Information  The following sets forth a reconciliation between our Adjusted EBITDA and net loss attributable to Adaptive Biotechnologies Corporation, the most directly compa

  11. Slide 11: Appendix: Segment information

    Appendix: Reconciliations between Adjusted EBITDA and net loss attributable to Adaptive Biotechnologies Corporation & Segment Information  The following sets forth segment information for each of the periods presented (in thousands): 11

Adaptive Biotechnologies — Q1 2026 Earnings Presentation on 6ix